Sana Biotechnology Inc (SANA) - Total Liabilities
Based on the latest financial reports, Sana Biotechnology Inc (SANA) has total liabilities worth $254.35 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Sana Biotechnology Inc equity growth rate to track the company's year-over-year net asset growth rate.
Sana Biotechnology Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data.
Sana Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Sana Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
USA | $7.55 Billion |
|
Jiangxi Xinyu Guoke Technology Co Ltd Class A
SHE:300722
|
China | CN¥223.36 Million |
|
CWB Automotive Electronics Co Ltd
SHG:605005
|
China | CN¥558.55 Million |
|
Beijing E Hualu Info Tech
SHE:300212
|
China | CN¥9.30 Billion |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
China | CN¥4.44 Billion |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
China | CN¥801.16 Million |
|
Great-Sun Foods Co Ltd
SHG:603336
|
China | CN¥341.42 Million |
|
Central Reinsurance Corp
TW:2851
|
Taiwan | NT$38.63 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Sana Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SANA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sana Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sana Biotechnology Inc (2018–2025)
The table below shows the annual total liabilities of Sana Biotechnology Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $256.01 Million | +2.19% |
| 2024-12-31 | $250.52 Million | -9.82% |
| 2023-12-31 | $277.79 Million | -14.10% |
| 2022-12-31 | $323.40 Million | -19.33% |
| 2021-12-31 | $400.90 Million | -65.18% |
| 2020-12-31 | $1.15 Billion | +106.46% |
| 2019-12-31 | $557.73 Million | +1073.66% |
| 2018-12-31 | $47.52 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more